In patients with CAD having percutaneous coronary intervention and stenting, they advise genotyping for CYP2C19 loss-of-function alleles and modifying the antiplatelet regimen depending on the genotyping outcomes [46]. This evidence concerns the gene CYP2C19 and coronary artery disorder.